Search for:

Ren Jun Lim

Ren Jun Lim is a principal with Baker McKenzie Wong & Leow. He represents local and international clients in both contentious and non-contentious intellectual property matters. He also advises on a full range of healthcare, as well as consumer goods-related legal and regulatory issues. Ren Jun co-leads Baker McKenzie Wong & Leow's Healthcare as well as Consumer Goods & Retail industry groups. He sits on the Law Society of Singapore IP Committee and on the Executive Committee of the Association of Information Security Professionals. He is also a member of the Vaccines Working Group, Singapore Association of Pharmaceutical Industries, a member of the International Trademark Association, as well as a member of the Regulatory Affairs Professionals Association. Ren Jun is ranked in the Silver tier for Individuals: Enforcement and Litigation and Individuals: Prosecution and Strategy, and a recommended lawyer for Individuals: Transactions by WTR 1000, 2020. He is also listed in Asia IP's Best 50 IP Expert, 2020, recognised as a Rising Star by Managing IP: IP Stars, 2019 and one of Singapore's 70 most influential lawyers aged 40 and under by Singapore Business Review, 2016. Ren Jun was acknowledged by WTR 1000 as a "trademark connoisseur who boasts supplementary knowledge of regulatory issues in the consumer products industry." He was also commended by clients for being "very responsive to enquiries and with a keen eye for detail, he is extremely hands-on. His meticulous and in-depth approach to strategising is key to the excellent outcomes we enjoy."

On 26 July 2023, the Ministry of Health launched the Industry Transformation Map (ITM) 2025 for healthcare. The ITM 2025 refreshes the ITM for healthcare, which was first launched in 2017.
ITM 2025 focuses on four main areas: (i) strengthening Singapore’s research and innovation ecosystem; (ii) strengthening digital system enablers; (iii) attracting and retaining healthcare workers; and (iv) strengthening partnerships.

On 13 July 2023, the Consumer Product Safety Office (CPSO) issued several notices to retailers and online sellers of products for children on the safety hazards posed by magnetic ball toys, water beads and electric toys containing button batteries that are improperly secured.
The CPSO stated that these products must not be supplied or sold if marketed directly or indirectly as a toy for children under 14 years old. Where consumers are reasonably able to infer that the product is a toy from the packaging, the packaging must clearly state that the product is not suitable for children below 14 years old, with at least one such statement in English.

On 17 July 2023, the Health Sciences Authority (HSA) proposed the new regulation for active ingredients under the Health Products Act.
Against the increasing complexity in the manufacturing and supply chain of active ingredients, streamlined and risk-based regulatory controls will ensure that active ingredients consistently meet appropriate quality standards. The HSA has therefore seen the need to consolidate and enhance regulatory controls for active ingredients under the Health Products Act.

On 27 July 2023, the Ministry of Health announced the rebranding of Singapore’s health tech agency, formerly known as the Integrated Health Information Systems to Synapxe.
The Ministry of Health also outlined five key priorities of Synapxe, namely: (i) national repository for patients’ medical records; (ii) system for remote healthcare; (iii) national billing system; (iv) strong cyber and data security; and (v) looking into the future and exploring possibilities, such as generative artificial intelligence.

On 18 July 2023, the PDPC issued two public consultation papers, seeking views on: (a) the proposed clarifications on how the PDPA applies to the collection and use of personal data to develop and deploy artificial intelligence (AI) systems that embed machine learning models used to make decisions, recommendations or predictions; and (b) the proposed Advisory Guidelines on the PDPA for children’s personal data, covering issues such as obtaining children’s consent, using children’s personal data and according higher standards of protection to children’s personal data.

In a recent decision by the Personal Data Protection Commission (PDPC) in Re Fullerton Healthcare Group Pte Limited and Agape CP Holdings Pte Ltd [2023] SGPDPC 5, the PDPC found that the respondents breached the protection obligation under the Personal Data Protection Act and ordered each of them to pay a financial penalty.

Phase 2 of the Healthcare Services Act 2020 (HCSA) has been implemented with effect from 26 June 2023. Under Phase 2, medical or dental healthcare providers who deliver services outside the premises of clinics and via teleconsultation will be required to hold a HCSA license, along with service providers offering outpatient medical and dental services, nuclear medicine, and outpatient renal dialysis, among others.